Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

47.36 -0.70 (-1.46%)
Official Closing Price Updated: 7:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
76 77 Next >
Bristol Myers' Drug Flunks Blood Cancer-Associated Anemia Trial
Bristol Myers' Reblozyl missed its primary goal in a Phase 3 anemia trial but showed positive secondary outcomes in myelofibrosis patients. 
Via Benzinga
Retail Chatter On BMY Doubles In 24 Hours With Drug Failing To Meet Primary Goal: Here's What Investors Are Thinking
Via Stocktwits
Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia
From Bristol Myers Squibb
Via Business Wire
Unpacking Q1 Earnings: Organon (NYSE:OGN) In The Context Of Other Branded Pharmaceuticals Stocks
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Organon (NYSE:OGN) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Bristol Myers, Pfizer To Offer Blood Thinning Drug At Discount: Retail Chatter Around BMY Jump 60% In 24 Hours
Via Stocktwits
Price Over Earnings Overview: Bristol-Myers Squibb
Via Benzinga
Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off
Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and nationwide delivery. 
Via Benzinga
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - An Undervalued Stock with Strong Fundamentals
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) is an undervalued pharmaceutical stock with strong profitability, a high dividend yield, and attractive valuation metrics, making it a candidate for value investors. 
Via Chartmill
Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option
From Bristol Myers Squibb
Via Business Wire
Don’t Miss These 4 Stocks With Explosive Dividend Yields
Via MarketBeat
Topics Stocks
Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?
BofA cuts Bristol Myers' 2025 EPS and sales estimates slightly and flags medium-term pressure from generics, while maintaining a Neutral rating. 
Via Benzinga
1 Safe-and-Steady Stock with Exciting Potential and 2 to Brush Off
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
Why Bristol-Myers Squibb (BMY) Shares Are Sliding Today
Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 3.5% in the afternoon session after a cautious analyst note from UBS highlighting significant upcoming expenses and other... 
Via StockStory
Topics ETFs Intellectual Property Stocks
Top S&P500 movers in Friday's session
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
What's going on in today's session: S&P500 movers
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday. 
Via Chartmill
Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday?
MiNK Therapeutics shares jumped as new clinical data show durable remission in testicular cancer and tumor reduction in gastric cancer using its iNKT cell therapy, agenT-797, in combination with... 
Via Benzinga
What's going on in today's session: S&P500 gap up and gap down stocks
Curious about the market action on Friday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest. 
Via Benzinga
Topics Government World Trade
2 Top Stocks Down 16% and 17% This Year to Buy and Hold
Via The Motley Fool
Topics Intellectual Property
Why Is AbbVie Stock Trading Higher On Thursday?
AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase clinical data. 
Via Benzinga
What Analysts Are Saying About Bristol-Myers Squibb Stock
Via Benzinga
Warren Buffett's Quiet Dividend Play: 9 High-Yield Stocks Held By A Berkshire Subsidiary
Warren Buffett is indirectly invested in high-dividend yield stocks via Berkshire Hathaway Inc.'s subsidiary New England Asset Management. 
Via Benzinga
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Merck (NYSE:MRK)
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Merck (NYSE:MRK) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Warren Buffett Owns 9 Ultra-High-Yield Dividend Stocks. Here's the Best of the Bunch.
Via The Motley Fool
Topics ETFs Regulatory Compliance
AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment
Via Benzinga
Is Pfizer Stock a Yield Trap?
Via The Motley Fool
Topics Intellectual Property
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Large-Cap Stocks Skating on Thin Ice
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for... 
Via StockStory
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers
FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment. 
Via Benzinga
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - A High-Yield Dividend Stock Worth Considering
BRISTOL-MYERS SQUIBB (NYSE:BMY) offers a high 5.29% dividend yield, strong profitability, and a reasonable valuation, making it a compelling choice for dividend investors. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
76 77 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.